Guardant Health, a prominent precision oncology company, has announced that Geisinger Health Plan will now cover its Guardant Reveal™ minimal residual disease (MRD) test. This blood test identifies circulating tumor DNA (ctDNA) post-treatment, assisting oncologists in pinpointing patients with lingering or recurring disease who might benefit from further therapy or monitoring.
Specifically, Geisinger will cover the test for individuals with stage II or III colorectal cancer after curative treatment. The coverage aligns with the National Comprehensive Cancer Network’s monitoring guidelines for colorectal cancer. Helmy Eltoukhy, Guardant Health’s chairman and co-CEO, expressed his satisfaction with Geisinger’s decision, emphasizing its potential to enhance outcomes for colorectal cancer patients. The Geisinger Health Plan’s decision further extends the payer coverage for Guardant Reveal, which had previously secured Medicare coverage in August 2022 and additional commercial payer coverage in July 2023.